Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Fudan University
- Enrollment
- 338
- Locations
- 1
- Primary Endpoint
- PFS
Study Overview
Brief Summary
This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.
Detailed Description
Patients with SNF2 subtype of HR+/HER2- advanced breast cancer confirmed by the Department of Pathology and Key Laboratory of Breast Cancer of Fudan University Affiliated Cancer Hospital are planned to be enrolled. Five treatment arms were set up based on the whether they have exposed to CDK4/6 inhibitors before. The main purpose is to evaluate immune therapy in SNF2 subtype of HR+/HER2- advanced breast cancer and prepare for subsequent randomized controlled phase III clinical studies with larger sample size.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Females ≥18 years and ≤ 75 years old;
- •Histologically confirmed HR + / HER2- invasive breast cancer (specific definition: immunohistochemical detection of ER> 10% tumor cell positive is defined as ER positive, PR> 10% tumor cell positive is defined as PR positive, ER and / or PR Positive is defined as HR positive; HER2 0-1 + or HER2 is ++ but negative followed by FISH detection, no amplification, defined as HER2 negative);
- •Subtype of similarity network fusion-2 (SNF-2) confirmed by the Department of Pathology and Key Laboratory of Breast Cancer of Fudan University Affiliated Cancer Hospital
- •Locally advanced breast cancer (incapable of radical local treatment) or recurrent metastatic breast cancer;
- •Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1); or unmeasurable lytic or mixed (osteolytic + osteoblastic) bone lesions in the absence of measurable lesions;
- •Has adequate bone marrow function: absolute neutrophil count > 1.5x10ˆ9 /L; platelet count > 75x10ˆ9 /L, hemoglobin > 9g/dL;
- •Patients had received no previous chemotherapy or targeted therapy for metastatic disease
- •Has adequate liver function and kidney function: serum creatinine
- •ECOG score ≤ 2 and life expectancy ≥ 3 months;
- •Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up.
Exclusion Criteria
- •Treatment with chemotherapy, radiotherapy, immunotherapy or surgery (outpatient clinic surgery excluded) for metastatic disease
- •Symptomatic, untreated, or actively progressing CNS metastases(glucocorticoids or mannitol needed to control symptoms);
- •Significant cardiovascular disease(including congestive heart failure, angina pectoris, myocardial infarction or ventricular arrhythmia in the last 6 months);
- •is pregnant or breast feeding;
- •Malignant tumors in the past five years (except cured skin basal cell carcinoma and cervical carcinoma in situ).
- •History of autoimmune disease
- •Positive test for human immunodeficiency virus
- •Active hepatitis B or hepatitis C
- •Uncontrolled pleural effusion and ascites
- •Thyroid dysfunction.
Arms & Interventions
Cohort 1A
In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with SHR1316 (anti-PD-L1) and endocrine therapy.
Intervention: SHR6390 (Drug)
Cohort 1A
In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with SHR1316 (anti-PD-L1) and endocrine therapy.
Intervention: SHR-1316 (Drug)
Cohort 1A
In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with SHR1316 (anti-PD-L1) and endocrine therapy.
Intervention: SERD (Drug)
Cohort 1A
In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with SHR1316 (anti-PD-L1) and endocrine therapy.
Intervention: AI (Drug)
Cohort 1B
In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with endocrine therapy.
Intervention: SHR6390 (Drug)
Cohort 1B
In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with endocrine therapy.
Intervention: SERD (Drug)
Cohort 1B
In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with endocrine therapy.
Intervention: AI (Drug)
Cohort 2A
In this cohort, a patient would receive SHR1316 (anti-PD-L1) combined with nab-paclitaxel.
Intervention: SHR-1316 (Drug)
Cohort 2A
In this cohort, a patient would receive SHR1316 (anti-PD-L1) combined with nab-paclitaxel.
Intervention: Nab paclitaxel (Drug)
Cohort 2B
In this cohort, a patient would single nab-paclitaxel.
Intervention: Nab paclitaxel (Drug)
Cohort 2C
In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with fulvestrant.
Intervention: SHR-1316 (Drug)
Cohort 2C
In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with fulvestrant.
Intervention: SERD (Drug)
Outcomes
Primary Outcomes
PFS
Time Frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)
time to progressive disease (according to RECIST1.1)
Secondary Outcomes
- ORR(Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years))
- CBR(Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years))
- OS(Randomization to death from any cause, through the end of study (approximately 5 years))
Investigators
Zhimin Shao
Professor
Fudan University